Neuroscientist expert in the neuro-drug-behavioral study of experimental models of human diseases, particularly in the field of neuropsychiatric mechanisms that underlie neurodegenerative processes such as Alzheimer's or Parkinson's. I co-founded ZeClinics in 2013 and since 2015, I have overseen its CNS Division, working on the implementation of new experimental trials related to CNS disorders using zebrafish. On the other hand, as ZeClinics CMO, I directed and coordinated all the marketing and branding activity of the company since its foundation, as well as supervising the implementation of Quality processes and the construction of the Human Resources department, for which I am still responsible. . In summer 2019 I co-founded the pharmaceutical company ZeCardio Therapeutics and in 2021 ZeLife Discovery, a company dedicated to exploiting our internal R&D. I am currently COO at ZeClinics, coordinating all the company's operations, with more than 45 employees distributed throughout the holding company and with a presence on five continents.